Feed

Oligometastatic disease (OMD) is considered an intermediate state between localized disease and widely metastatic disease, offering selected patients with metastatic esophageal cancer the possibility of long-term survival and even potential cure. In recent years, substantial progress has been made in oligometastatic esophageal cancer with advances in local treatment modalities, the widespread application of immunotherapy, and the development of precision medicine. In particular, randomized controlled evidence represented by the ESO-Shanghai 13 trial has, for the first time, demonstrated that local intervention combined with systemic therapy can provide significant survival benefits for patients with oligometastatic esophageal squamous cell carcinoma (ESCC), thereby promoting a shift in treatment strategy from purely palliative care to active multidisciplinary intervention. Meanwhile, the launch of the Oligometastatic Esophageal Squamous Cell Carcinoma (OMESQ) international consensus project marks the transition of oligometastatic ESCC research from borrowing experience from other tumor types toward disease-specific development. However, radiologically defined oligometastatic disease is not equivalent to biologically defined oligometastatic disease, and patient selection may be more important than the treatment modality itself. Based on recent advances in oligometastatic esophageal cancer, this commentary discusses the evolution of concepts, key clinical evidence, current controversies, and future directions. The author believes that research on oligometastatic esophageal cancer is moving from the exploratory stage of determining "whether local treatment is effective" toward a new stage of determining "how to precisely identify patients who are most likely to benefit." Establishing an ESCC-specific treatment framework based on tumor biological characteristics will become an important future direction in this field.